Welcome to our dedicated page for Masimo Corporation news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo Corporation stock.
Masimo Corporation (NASDAQ: MASI) is a leading global medical technology company specializing in the development and manufacturing of innovative noninvasive patient monitoring technologies. For over 27 years, Masimo has been at the forefront of medical advancements, offering a wide array of sensors and devices that enhance patient care and safety. Their products are designed to provide healthcare professionals with critical information to improve clinical decision-making.
Masimo's core business is divided into two segments: healthcare and non-healthcare. The healthcare segment is the primary revenue generator, focusing on noninvasive patient monitoring technologies, hospital automation, connectivity solutions, and remote monitoring devices. Their clinically proven products are widely used in hospitals, emergency rooms, and clinical settings around the world.
The non-healthcare segment encompasses the consumer audio business, which includes the development, manufacturing, marketing, and licensing of premium and luxury audio sound products. This segment is known for its advanced audio integration technologies that appeal to audiophiles and general consumers alike.
Masimo's recent achievements include expanding their product portfolio with advanced remote monitoring solutions, partnering with leading healthcare organizations, and pioneering innovative technologies that address unsolvable medical challenges. Financially, the company is robust, showing consistent growth and a strong market presence.
Masimo’s dedication to improving lives is evident in their mission to save, extend, and enhance the quality of life across all demographics. Their innovative spirit attracts individuals who are passionate about making a significant impact in the medical field. As they continue to innovate, Masimo remains committed to providing top-tier products that meet the evolving needs of the healthcare industry.
Masimo (MASI) reported a strong first quarter 2021, with product revenue soaring by 10.9% to $299.0 million. Excluding certain products, noninvasive technology shipments were 66,000, down from 72,100 year-over-year. GAAP net income decreased to $53.4 million or $0.92 per diluted share, compared to $64.5 million or $1.12 in the previous year. For 2021, the company updated guidance to project total revenue of $1.205 billion, reflecting a 5.4% growth rate, and $3.83 earnings per diluted share.
Masimo (NASDAQ: MASI) has rescheduled its first quarter 2021 financial results release to April 26, 2021, due to executive scheduling changes. The conference call will commence at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by CEO Joe Kiani and CFO Micah Young. Participants can register for the call to receive their unique dial-in details. Masimo is recognized for its advanced medical monitoring technologies aimed at enhancing patient outcomes and reducing healthcare costs, notably with its SET® pulse oximetry technology, which is widely adopted in leading hospitals.
Masimo (NASDAQ: MASI) will release its first quarter 2021 financial results on April 27, 2021, after market close. The conference call for discussing the results, hosted by CEO Joe Kiani and CFO Micah Young, will start at 1:30 p.m. PT (4:30 p.m. ET). Participants can register for the call via a provided link. Masimo is known for its innovative medical monitoring technologies, including the widely used Masimo SET® pulse oximetry, which is critical in improving patient outcomes and minimizing healthcare costs.
Masimo (NASDAQ: MASI) announced FDA 510(k) clearance for its portable Radius PCG™, a wireless capnograph that offers quick and accurate end-tidal carbon dioxide (EtCO2) and respiration rate measurements. Designed for seamless integration with the Root® Patient Monitoring Platform, Radius PCG does not require routine calibration and displays results in 15 seconds. Key features include cable-free operation, automated documentation, enhanced data visibility, and easy Bluetooth connectivity. This device enhances patient monitoring and clinical workflows, especially in emergency settings.
Masimo (NASDAQ: MASI) will present at the 20th Annual Needham Healthcare Conference on April 12, 2021, at 3:45 p.m. Eastern Time. A live webcast will be accessible on the Masimo website, with a replay available post-event. As a leader in medical technology, Masimo develops advanced monitoring solutions to improve patient outcomes and lower care costs. Its industry-standard SET pulse oximetry technology, used in over 100 million patients globally, demonstrates superior performance in critical scenarios. For more details, visit www.masimo.com.
Masimo (NASDAQ: MASI) has released findings from a prospective observational study published in Critical Care, evaluating the effects of various rescue therapies on oxygenation in mechanically ventilated COVID-19 patients with ARDS. The study utilized the Masimo Root® Patient Monitoring platform along with O3® Regional Oximetry. Researchers assessed therapies like recruitment maneuvers, prone positioning, inhaled nitric oxide, and ECCO2R. Results indicated diverse impacts on cerebral oxygenation, stressing the significance of tailored rescue strategies for patient care.
Masimo (NASDAQ: MASI) announced a study published in Acta Paediatrica evaluating the accuracy of its Rad-G™ device's plethysmographic respiration rate measurement (RRp®) in malnourished children hospitalized in Nigeria. Conducted with 514 children, the study found Rad-G's RRp readings aligned closely with manual counts, classifying respiratory rates correctly 84% of the time. The results suggest a significant clinical potential for automated RR counting over manual methods. Masimo's Rad-G is designed for resource-limited environments, enhancing patient care efficiency.
Masimo (NASDAQ: MASI) announced a study in Sri Lanka Journal of Child Health evaluating pulse oximetry for critical congenital heart disease (CCHD) screening in newborns. The study demonstrated a CCHD detection rate of 91% using Masimo SET® pulse oximetry versus 82% for physical exams. Combining both methods led to a 100% detection rate. Researchers advocated for routine implementation in maternity units. Masimo SET® has shown superior performance in past studies, further establishing its reliability in clinical settings.
Masimo (NASDAQ: MASI) published findings from a study in Pediatrics International demonstrating the effectiveness of its EMMA® Portable Capnograph in monitoring respiratory conditions in children with tracheostomy. Conducted by Osaka Women’s and Children’s Hospital, the study revealed a strong correlation (0.87) between end-tidal carbon dioxide (EtCO2) and venous carbon dioxide (PvCO2) measurements, positioning the EMMA device as a valuable tool for non-invasive respiratory assessments. The research highlighted its portability and rapid result delivery, applicable in home-care and outpatient settings.
Masimo (NASDAQ: MASI) emphasizes its commitment to enhancing maternal and newborn safety through innovative monitoring solutions. Their Masimo SET® pulse oximetry technology aids in critical areas like detection of retinopathy of prematurity and congenital heart disease. A recent study indicates that comparing perfusion index values in pre-term infants can improve diagnosis for patent ductus arteriosus. Masimo's products aim to provide precise measurements, especially during neonatal emergencies, and have gained recognition in both U.S. and global healthcare standards.
FAQ
What is the current stock price of Masimo Corporation (MASI)?
What is the market cap of Masimo Corporation (MASI)?
What is Masimo Corporation's main business?
How long has Masimo Corporation been in operation?
What are the key segments of Masimo's business?
What products does Masimo offer?
What makes Masimo's products unique?
Who uses Masimo's healthcare products?
What recent achievements has Masimo Corporation accomplished?
What is the financial status of Masimo Corporation?
What is Masimo's mission?